Educational article
Weight-loss pills without diabetes: oral GLP‑1 medicines and options to review
Educational content. It does not replace an individual medical assessment and should not be used for self-medication.

Why the decision starts with your history
Obesity without diabetes can be a reason to discuss weight-management medication. The choice depends on history, previous treatment, interactions and goals. Include products bought without a prescription and describe what you hoped they would achieve.
How oral options differ
Some options act on appetite while others, such as orlistat, affect intestinal fat absorption. Oral semaglutide acts on GLP‑1, while other combinations have different mechanisms and precautions. Compare the product’s indication and relevant medical history with the doctor.
What is known about oral semaglutide
OASIS studied an oral semaglutide formulation in adults with obesity or overweight and related conditions without diabetes. Average weight reduction was greater than with placebo. The comparison informs discussion of that formulation and the trial setting, including digestive side effects.
What has changed in this year’s options
As of November 2026, official FDA prescribing information includes Wegovy tablets for adults with defined weight-management and cardiovascular indications. That authorization applies to the United States. Use in Colombia requires checking the product’s INVIMA registration, indication and actual availability.
What is known about orforglipron
Another oral option approved by the FDA in 2026 is orforglipron, marketed as Foundayo in the United States. Its weight-management indication is used alongside nutrition and activity. Reported adverse effects include digestive symptoms. Registration, precautions and availability need to be checked for the country where you receive care.
How to compare effectiveness and safety
When reading a list of the “best pills”, check whether similar populations are compared and whether adverse effects and discontinuations are included. Useful treatment also needs to be manageable and followed over time. Ask what response would be reviewed and what might prompt a change.
What to discuss before deciding
Mention pregnancy plans, digestive conditions, other treatment and difficulty eating or drinking. Oral formulations have product-specific instructions. Severe symptoms or sudden vision loss warrant prompt assessment and a report of the product being used.
Review your situation with the doctor
Attend an in-person or virtual consultation with Dr. Teresita Cortés at Endomédicos to review your history, questions and follow-up. Bring available reports and a list of the products you use.
When to seek medical care
If symptoms persist, test results are abnormal, or you have questions about medication, arrange an individual assessment. Do not change treatment or doses without medical guidance.
Frequently asked questions
Is one pill best for everyone without diabetes?
Comparison requires medical history, indication, tolerability and access. Attend a consultation to review your alternatives.
Does an approval announcement mean it is sold in Colombia?
Approval and availability need to be checked for the country and exact formulation.
References
- Oral semaglutide in adults with overweight or obesity, OASIS trial · New England Journal of Medicine
- Wegovy, official prescribing information for injection and tablets · FDA
- FDA approval of Foundayo, orforglipron, for weight management · FDA
- Autorización de comercialización y registros sanitarios de medicamentos · INVIMA
- Prescription medications to treat overweight and obesity · NIDDK
Does this topic resonate with you?
Every case is different. Book a consultation to review your history, test results and goals with a personalized plan.


